NCT05268107招募中4 期
Ethnic Differences in Mechanisms of Action of Dupilumab
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 (IL4) from week 0 to 2.
研究概览
简要总结
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.
This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD.
The central hypothesis of this study is that ethnic differences in both immune and stromal cells contribute to variability in AD presentation and response to anti-interleukin-4 receptor (IL-4R) inhibition with dupilumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Established diagnosis of AD for at least 2 years before the screening visit and confirmed according to the American Academy of Dermatology Consensus Criteria at the time of the screening visit
- •Moderate-to-severe AD with involvement > 10% of body-surface-area (BSA) and investigator global assessment (IGA) score 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits
- •Female subjects of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree either to commit to true abstinence throughout the study and for 12 weeks after the last study drug injection or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection
- •Subject willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol
排除标准
- •Body weight less than 30 kilogram
- •Subjects meeting 1 or more of the following criteria at screening or baseline:
- •Had an exacerbation of asthma requiring hospitalization in the preceding 12 months.
- •Reporting asthma that has not been well-controlled (ie, symptoms occurring on >2 days per week, nighttime awakenings 2 or more times per week, or some interference with normal activities) during the preceding 3 months
- •Asthma Control Test (ACT) < 19 (only for subjects with a history of asthma).
- •Subjects with a current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis.
- •Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.
- •Confirmed or suspected coronavirus disease 2019 (COVID-19) infection within 4 weeks before the screening or baseline visit
- •Received COVID-19 vaccination within 4 weeks before baseline visit
- •Previous treatment with dupilumab
- •Pregnant women (positive serum pregnancy test result at the screening visit or positive urine pregnancy test at the baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study
- •History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the baseline visit
- •History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, i.e., monoclonal antibody) or to lidocaine
- •Known active or latent tuberculosis (TB) infection
- •Known or suspected immunosuppression or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment
- •History of or current confounding skin condition (i.e., Netherton syndrome, psoriasis, cutaneous T-cell lymphoma [mycosis fungoides or Sezary syndrome], contact dermatitis, chronic actinic dermatitis, dermatitis herpetiformis)
- •Planned or expected major surgical procedure during the study
- •Currently participating or participated in any other study of a drug or device, within the past 8 weeks before the screening visit, or is in an exclusion period (if verifiable) from a previous study
- •History of alcohol or substance abuse within 6 months of the screening
- •History of poor wound healing or keloid formation
研究组 & 干预措施
Dupilumab
Experimental
The 3 groups of patients (Asian, African American, and Caucasian) will all receive the same intervention.
干预措施: Dupilumab (Drug)
结局指标
主要结局
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 (IL4) from week 0 to 2.
时间窗: Week 0, week 2
次要结局
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin13 from week 0 to 2.(Week 0, week 2)
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of Interferon (IFN) from week 0 to 2.(Week 0, week 2)
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin36 from week 0 to 2.(Week 0, week 2)
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 from week 0 to 16.(Week 0 to week 16)
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin13 from week 0 to 16.(Week 0 to week 16)
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of IFN from week 0 to 16.(Week 0 to week 16)
- Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin36 from week 0 to 16.(Week 0 to week 16)
研究者
Johann E Gudjonsson MD PhD
Professor of Dermatology
University of Michigan
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic ProbandsAtopic DermatitisNCT00509535L'Oreal75
已完成
2 期
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus HydrocortisoneDermatologic DiseaseNCT05607901Tanta University100
已完成
不适用
Atopic Dermatitis: Sub-Saharan Africa vs. Central EuropeAtopic DermatitisNCT05363904University of Zurich240
已完成
4 期
Tacrolimus Versus Hydrocortisone in Atopic DermatitisAtopicDermatitisNCT05324618Ain Shams University200
已完成
3 期
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema TreatmentEczemaNCT01257061EMS310